Dose‐dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial

201930 citationsJournal Articlehybrid Open Access

Authors

Claire Baker · Diabetes & Endocrine Associates

Suman Wason · Lexicon Pharmaceuticals (United States)

Phillip Banks · Lexicon Pharmaceuticals (United States)

Sangeeta Sawhney · Lexicon Pharmaceuticals (United States)

Anna Chang · John Muir Health

Thomas Danne · Kinderkrankenhaus auf der Bult

Diane Gesty‐Palmer

Abstract

Combined with stable insulin doses, sotagliflozin 200 mg and 400 mg improved glycaemic control and weight in adults with T1D. Sotagliflozin 400 mg reduced PPG levels. UGE increased with all sotagliflozin doses. Rates of severe hypoglycaemia and DKA were low (NCT02459899).

Topics & Keywords

Diabetes Treatment and Management Diabetes Management and Research Pancreatic function and diabetes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

Volume 21, Issue 11, pp. 2440-2449

DOI: 10.1111/dom.13825

Field-Weighted Citation Impact: 3.02